Patents by Inventor Eric Schordan

Eric Schordan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-coding RNAS (NCRNA) for the diagnosis of cognitive disorders
    Patent number: 11718879
    Abstract: The present invention describes a method for the diagnosis of a cognitive disorder including but not limited to Alzheimer disease in a subject at risk of having or developing a cognitive disorder.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: August 8, 2023
    Assignee: AMONETA DIAGNOSTICS
    Inventors: Hueseyin Firat, Saliha Moussaoui, Eric Schordan
  • Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders
    Patent number: 11667974
    Abstract: The present invention provides methods for the diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessment/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the assessment of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different cardiac pathophysiological events and represent a potential target for therapeutical approaches.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: June 6, 2023
    Assignees: FIRALIS SA, LUXEMBOURG INSTITUTE OF HEALTH, THE UNIVERSITY HOSPITAL OF LAUSANNE, THE CARDINAL STEFA WUSZYNSKI INSTITUTE OF CARDIOLOGY
    Inventors: Hueseyin Firat, Sabrina Danilin, Yvan Devaux, Lu Zhang, Przemyslaw Leszek, Eric Schordan, Samir Ounzain, Thierry Pedrazzini
  • LONG NON-CODING RNAS (LNCRNAS) FOR THE DIAGNOSIS AND THERAPEUTICS OF BRAIN DISORDERS, IN PARTICULAR COGNITIVE DISORDERS
    Publication number: 20210269881
    Abstract: The present invention describes a method for the therapeutic treatment and/or for the diagnosis of a brain disorder including but not limited to cognitive disorders such as mild cognitive impairment, Alzheimer disease, frontotemporal dementia, dementia with Lowy body in a subject at risk of having or developing a brain disorder such as cognitive disorder, using long non-coding RNA (IncRNA).
    Type: Application
    Filed: September 5, 2019
    Publication date: September 2, 2021
    Inventors: Saliha MOUSSAOUI, Hueseyin FIRAT, Eric SCHORDAN
  • DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC USES OF LONG NONCODING RNAs FOR PATHOLOGIES AND TOXICITIES INDUCING HEART DISORDERS
    Publication number: 20210189491
    Abstract: The present invention provides methods for the diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessment/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the assessment of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different cardiac pathophysiological events and represent a potential target for therapeutical approaches.
    Type: Application
    Filed: June 12, 2018
    Publication date: June 24, 2021
    Inventors: Hueseyin FIRAT, Sabrina DANILIN, Yvan DEVAUX, Lu ZHANG, Przemyslaw LESZEK, Eric SCHORDAN, Samir OUNZAIN, Thierry PEDRAZZINI
  • NON-CODING RNAS (NCRNA) FOR THE DIAGNOSIS OF COGNITIVE DISORDERS
    Publication number: 20210071252
    Abstract: The present invention describes a method for the diagnosis of a cognitive disorder including but not limited to Alzheimer disease in a subject at risk of having or developing a cognitive disorder.
    Type: Application
    Filed: September 5, 2018
    Publication date: March 11, 2021
    Inventors: Hueseyin FIRAT, Saliha MOUSSAOUI, Eric SCHORDAN
  • Use of PTHrP antagonists for treating renal cell carcinoma
    Patent number: 7727526
    Abstract: The present invention concerns the use of a PTHrP antagonist for preparing a pharmaceutical composition for treating renal cell carcinoma (RCC) in a mammal and in particular in a human subject. Advantageously, the invention is of particular interest for inhibiting or reducing tumour growth and/or metastasis formation in kidney cancer and its metastatic developments, in particular in the lung and the liver.
    Type: Grant
    Filed: July 4, 2003
    Date of Patent: June 1, 2010
    Assignees: Universite Louis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM), Hopitaux Universitaires de Strasbourg
    Inventors: Thierry Massfelder, Herve Lang, Eric Schordan, Jean-Jacques Helwig
  • Use of pthrp antagonists for treating renal cell carcinoma
    Publication number: 20060003916
    Abstract: The present invention concerns the use of a PTHrP antagonist for preparing a pharmaceutical composition for treating renal cell carcinoma (RCC) in a mammal and in particular in a human subject. Advantageously, the invention is of particular interest for inhibiting or reducing tumour growth and/or metastasis formation in kidney cancer and its metastatic developments, in particular in the lung and the liver.
    Type: Application
    Filed: July 4, 2003
    Publication date: January 5, 2006
    Inventors: Thierry Massfelder, Eric Schordan, Jean-Jacques Helwig